SCHEMBL30859901

SCHEMBL30859901

CN(CCC(=O)N1CCN(C(=O)C2CC2)CC1)C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.49
HPGD P15428 2/20 0.44
RECQL P46063 1/20 0.42
HSD11B1 P28845 2/20 0.41
LSS P48449 1/20 0.40
CTSD P07339 1/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
ALDH1A1 P00352 3/20 0.37
HTT P42858 2/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 2/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
EPHX2 P34913 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNA3 P32297 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9354894 0.83 CTSD (0.40) HPGDCTSDCTSLCTSBCTSS
SCHEMBL19200747 0.82 KMT2A (0.42) HPGDCTSDCTSLCTSBCTSS
SCHEMBL9354413 0.80 CTSD (0.39) HSD11B1CTSDCTSLCTSBCTSS
SCHEMBL9355336 0.80 CTSD (0.56) RECQLCTSDCTSLCTSBCTSS
SCHEMBL23138479 0.77 HPGD (0.48) TP53HPGDRECQLHSD11B1LSS
SCHEMBL23138545 0.77 HTT (0.50) TP53HPGDRECQLHSD11B1LSS
SCHEMBL23138544 0.77 HTT (0.50) TP53HPGDRECQLHSD11B1LSS
SCHEMBL23138509 0.75 HPGD (0.56) TP53HPGDRECQLLSSALDH1A1
SCHEMBL1561382 0.75 ATM (0.49) HPGDCTSDCTSLCTSBCTSS
SCHEMBL30859928 0.75 SIGMAR1 (0.53) TP53HPGDRECQLHSD11B1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 US disclosed
EP-4594314-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS Azkarra Therapeutics, Inc. (US) 2025-08-06 EP disclosed
CN-119968364-A Pyridazin-3 (2H) -one and pyridin-2 (1H) -one PARP inhibitor compounds 阿兹卡拉疗法公司 2025-05-09 CN disclosed
WO-2024073133-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 TP53 1475/4885HPGD 2503/4885RECQL 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.